Last reviewed · How we verify
misoprostol 800 µg
At a glance
| Generic name | misoprostol 800 µg |
|---|---|
| Sponsor | Aswan University Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Rectal Misoprostol for Reducing Blood Loss in Elective Cesarean Section (NA)
- Termination Of Anembryonic Pregnancy (PHASE2)
- Mifepristone and Two Doses of Misoprostol for Abortion at 11&12 Weeks (PHASE4)
- Misoprostol for Management of Women With an Incomplete Miscarriage (NA)
- Oxytocin Versus, Sublingual Misoprostol in the Secondary Prevention of Postpartum Hemorrhage After Vaginal Delivery (NA)
- Management of Women With an Incomplete Miscarriage (NA)
- Two Different Regimens of Misoprostol in Retained Placenta (PHASE2)
- Medical Abortion at Gestational Age of 8 to ≤9 Weeks Versus >9 to ≤12 Weeks (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- misoprostol 800 µg CI brief — competitive landscape report
- misoprostol 800 µg updates RSS · CI watch RSS
- Aswan University Hospital portfolio CI